戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CYP27A1 exhibited only three Lys residues, Lys(134), Lys
2                                              CYP27A1 is considered a potential therapeutic target in
3                                              CYP27A1 may participate in the removal of harmful autoxi
4                                              CYP27A1 was shown to mediate the reduction of cholestero
5                        Cytochrome P450 27A1 (CYP27A1 or sterol 27-hydroxylase) is a ubiquitous, multi
6                        Cytochrome P450 27A1 (CYP27A1) is a ubiquitous enzyme that hydroxylates choles
7          Mitochondrial cytochrome P450 27A1 (CYP27A1) is a ubiquitous multifunctional sterol C27-hydr
8                        Cytochrome P450 27A1 (CYP27A1) is a ubiquitously expressed mitochondrial stero
9  alteration in genes including ACAT1, ACAT2, CYP27A1, ABCA1, GPAT2, PNPLA2, PGC1alpha, and Nrf2.
10 bufagenin levels doubled, and adrenocortical CYP27A1 mRNA and protein increased 1.6-fold and 2.0-fold
11  T110, M301C, V367, I481, and V482) affected CYP27A1 binding and enzyme activity in a substrate-depen
12 and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes.
13                                  CYP11A1 and CYP27A1 hydroxylate tachysterol(3) , a photoproduct of p
14 ession of the VD metabolism genes CYP2R1 and CYP27A1 (25-hydroxylase), CYP27B1 (1-alpha-hydroxylase),
15               Expression of VDR, CYP2R1, and CYP27A1 was evaluated via immunohistochemistry in hepato
16 with NASH and CHC expressed VDR, CYP2R1, and CYP27A1.
17 nocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in
18 vitamin D receptor, retinoid X receptor, and CYP27A1 in BALF cells of patients infected with SARS-CoV
19                                         Both CYP27A1 and CYP46A1 are expressed in primate retina indi
20 27HC), a derivative of cholesterol formed by CYP27A1, can mobilize cholesterol from the lysosomes to
21 tion, we identified three enzyme candidates: CYP27A1, CYP1A1, and CYP1B1.
22 ble for production of 27HC from cholesterol, CYP27A1, is expressed primarily in the liver and in macr
23                                     Complete CYP27A1 deficiency owing to genetic mutations is detrime
24                          In humans, complete CYP27A1 deficiency leads to cerebrotendinous xanthomatos
25 ry of cholesterol to mitochondria containing CYP27A1.
26               Additionally, CYP7A1, CYP11A1, CYP27A1, and CYP46A1 are parts of a broader cholesterol
27 dR) and tightly associated (CYP7B1, CYP11A1, CYP27A1, and CYP46A1) membrane proteins were quantified.
28  cytochrome P450 (CYP) isoform 7A1 (CYP7A1), CYP27A1, CYP8B1, uridine 5'-diphospho-glucuronosyltransf
29 cally downregulated genes identified encodes CYP27A1, an enzyme involved in regulating cellular chole
30  acid pathway, which is controlled by enzyme CYP27A1.
31 HC), synthesized by the mitochondrial enzyme CYP27A1, was identified as one of the major de novo adip
32 ordinated by the LXR-ligand-producing enzyme CYP27A1, which was upregulated in damaged intestinal cry
33 es encoding the bile acid metabolism enzymes CYP27A1 and CYP3A11 as well as canalicular bile salt pum
34  cholesterol 25-hydroperoxide to the enzymes CYP27A1 and CYP11A1 induced well-defined spectral change
35 d at the protein level by immunostaining for CYP27A1 in annotated tissue microarrays.
36 s as immune modulators and a direct role for CYP27A1 in generating these RORgammat agonist ligands, w
37 n cholestanol in the cerebellum arising from CYP27A1 deficiency.
38 plain in part why humans who lack functional CYP27A1 do not display a corresponding increase in CYP3A
39 isms (SNPs) of five vitamin D-related genes (CYP27A1, CYP2R1, CYP27B1, GC and VDR) were genotyped in
40 brosis stage was associated with low hepatic CYP27A1 expression, whereas portal inflammation was sign
41 related neurodegenerative diseases; however, CYP27A1 inhibition should be </=50%.
42        Hydrophobic bile acids suppress human CYP27A1 gene reporter activity when assayed in human hep
43                   Results suggest that human CYP27A1 gene transcription is suppressed by bile acids a
44  a region downstream of nt -147 of the human CYP27A1 gene, within which a binding site for a liver-sp
45         Mitochondrial sterol 27-hydroxylase (CYP27A1) catalyses sterol side-chain oxidation of bile a
46 lassical pathway, and sterol 27-hydroxylase (CYP27A1) initiates the hydroxylation of cholesterol in t
47                       Sterol 27-hydroxylase (CYP27A1) is required for bile acid synthesis by both the
48 se (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1).
49                            Mice deficient in CYP27A1, a key enzyme in generating these oxysterols, sh
50 st-translational modifications identified in CYP27A1 exemplify a general mechanism whereby oxidative
51 a lipid storage disorder due to mutations in CYP27A1, typically characterized by DN damage.
52  (dasatinib) elicited a spectral response in CYP27A1 and had Ki values for cholesterol 27-hydroxylati
53 xi-hydroperoxides induced spectral shifts in CYP27A1 and CYP11A1 but glycol metabolites were detected
54                      Bile acids also inhibit CYP27A1 reporter activity in human embryonic kidney 293
55                  Of them, 14 drugs inhibited CYP27A1 by >/=75% and were evaluated for in vitro bindin
56 c analysis revealed homozygosity for a known CYP27A1 mutation (c.1263+1G --> A) in the 3 symptomatic
57 ation of an internal standard, (15)N-labeled CYP27A1 modified with iso[4]LGE(2), for the subsequent a
58 ensive ophthalmic evaluation of mice lacking CYP27A1.
59                           Importantly, lower CYP27A1 transcript levels were associated with shorter d
60  a biochemical activity similar to mammalian CYP27A1 catalyzing addition of a terminal acid to the si
61 pathway, which is initiated by mitochondrial CYP27A1.
62         These data demonstrate that modified CYP27A1 is present in the retina.
63 ere diagnosed (mutations in PAH, CBS, MTHFR, CYP27A1, and HIBCH), and in 1 family, 2 disease-causing
64  of CYP46A1 and high cerebellar abundance of CYP27A1, the lack of which probably selectively increase
65    The present work assessed druggability of CYP27A1 as a potential antibreast cancer target.
66 renocortical cells reduced the expression of CYP27A1 mRNA by 70%, reduced total bile acids 2-fold, an
67                       However, expression of CYP27A1, the rate-determining enzyme in the alternate pa
68                                Inhibition of CYP27A1 activity or knockdown and deletion of the Cyp27a
69                  We found that inhibition of CYP27A1 through inhibitors and siRNA knockdown did not n
70  have unanticipated off-target inhibition of CYP27A1, and we propose strategies for their identificat
71                    Ablation or inhibition of CYP27A1, the enzyme responsible for the rate-limiting st
72 cancer specimens exhibited reduced levels of CYP27A1, LXR target genes, and B and CD8 T cell gene sig
73                                      Loss of CYP27A1 in prostate cancer was confirmed at the protein
74                    We found that the loss of CYP27A1 led to dysregulation of retinal cholesterol home
75         Our results enhance the potential of CYP27A1 as an antibreast cancer target, could be of impo
76 ycholesterol (27HC), an enzymatic product of CYP27A1, reduced cellular cholesterol content in prostat
77                               Restoration of CYP27A1 expression in cells where its gene was silenced
78 poietic stem/progenitor cells as a result of CYP27A1, a cholesterol hydroxylase.
79 opic eczema was associated with rs4674343 of CYP27A1 (odds ratio 0.66, 95% confidence interval 0.53-0
80 rmaceuticals were tested for their effect on CYP27A1-mediated cholesterol 27-hydroxylation by in vitr
81         A vitamin D-related SNP rs4674343 on CYP27A1 was found to be protective against atopic eczema
82           Cytochrome P450 27A1 (P450 27A1 or CYP27A1) is an important enzyme that participates in dif
83 been discovered, initiated by CYP11A1 and/or CYP27A1 in the case of L3 and T3.
84                       Mutations in CYP7B1 or CYP27A1, which encode enzymes involved in cholestenoic a
85 rsion to 27HC by the cytochrome P450 oxidase CYP27A1 and were attenuated by treatment with CYP27A1 in
86                              Cytochrome P450 CYP27A1 is the only enzyme in humans converting choleste
87 th sterol 27-hydroxylase, a cytochrome P450 (CYP27A1); however, the identity of the microsomal enzyme
88 shed for the retina, where cytochromes P450 (CYP27A1 and CYP46A1) are the major cholesterol-metaboliz
89 l as the scaffold with potential for partial CYP27A1 inhibition in humans.
90                          Thus, pharmacologic CYP27A1 inhibition is possible in the whole body and ind
91 nerative storage disease caused by recessive CYP27A1 mutations and is characterized by abnormal depos
92 vitro for inhibition of purified recombinant CYP27A1 and binding to the enzyme active site.
93            Treatment of purified recombinant CYP27A1 with authentic iso[4]levuglandin E(2) (iso[4]LGE
94            In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade.
95                HNF4alpha strongly stimulates CYP27A1 gene transcription and mutation of its binding s
96                                   Six strong CYP27A1 inhibitors/binders were identified.
97 e is known about its metabolism, except that CYP27A1 might metabolize cholestanol.
98       We confirmed our previous finding that CYP27A1 is a druggable enzyme and found additional drugs
99                    Our findings suggest that CYP27A1 is a critical cellular cholesterol sensor in pro
100        Mutation of Arg-418, conserved in the CYP27A1 family, to serine also decreased the affinity fo
101 w that post-transcriptional silencing of the CYP27A1 gene in human trophoblast and rat adrenocortical
102 chondrial cytochrome P450c27 (product of the CYP27A1 gene) is found to have significantly higher affi
103                      Distinct binding of the CYP27A1 substrates may provide insight into why phenotyp
104 prostate cells and that dysregulation of the CYP27A1/27HC axis contributes significantly to prostate
105 ity toward the CYP24 enzyme in comparison to CYP27A1 (IC(50) > 1000 nM) and CYP27B (IC(50) = 554 nM).
106 trocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not appar
107 ed in the bypass of peripheral TOMs, whereas CYP27A1 interacted only with Hsp70 and was not able to b
108                       It also is unclear why CYP27A1 deficiency results in preferential cholestanol a
109             We quantified sterols along with CYP27A1 and CYP46A1 in mouse models (Cyp27a1(-/-), Cyp46
110 ous xanthomatosis, a disease associated with CYP27A1 deficiency, are so diverse.
111 e-3alpha,7alpha,12alpha-triol, interact with CYP27A1.
112 YP27A1 and were attenuated by treatment with CYP27A1 inhibitors.

 
Page Top